Sunday, January 23, 2022 6:32:04 PM
sentiment_stocks,
Absolutely correct. In the rules concerning exceptions to adequate and well controlled trials there are only two time points for the SAP to occur and they are at the beginning of the trial or at the end. Because of the adaptive trial design they would have chosen to make sure the SAP was done at the end of this trial which is when they said they were working on it. There have also been recent reported comments attributed to NWBO attesting there has only ever been one SAP.
Excellent observation and it kind of puts a big monkey wrench into the failed trial or futility argument as the endpoints could not have been measured with an SAP even if futility could be argued for based on unadjudicated measures found in the original leaked protocol. Something tells me that this is what the bears were hoping would stick, especially if someone close to the trial said something off the record inline with this. Thank you and best wishes.
Absolutely correct. In the rules concerning exceptions to adequate and well controlled trials there are only two time points for the SAP to occur and they are at the beginning of the trial or at the end. Because of the adaptive trial design they would have chosen to make sure the SAP was done at the end of this trial which is when they said they were working on it. There have also been recent reported comments attributed to NWBO attesting there has only ever been one SAP.
Excellent observation and it kind of puts a big monkey wrench into the failed trial or futility argument as the endpoints could not have been measured with an SAP even if futility could be argued for based on unadjudicated measures found in the original leaked protocol. Something tells me that this is what the bears were hoping would stick, especially if someone close to the trial said something off the record inline with this. Thank you and best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
